INTRODUCTION

Breast cancer remains a leading cause of death of women all over the world. Presentation of patients with this cancer in late stage (Manchester III and IV) is rare in the Western World (1). On the contrary, late stage presentation is common in developing countries especially so in the African sub-continent. In this region the prevalence of advanced breast cancer at presentation ranges between 57 and 95% (1-5). Patient delay defines the time lapse between noticing a breast symptom and presenting to the healthcare provider or facility. Randomised trials have established that patient delay of three or more months at presentation is associated with significantly higher levels of recurrence and lower survival rates (6,7). Patient delay accounts for a large proportion of those who present with late stage disease especially in developing countries. Understanding the factors that influence patient delay is critical in order to develop effective and targeted interventional programmes to shorten this delay and hence provide women suffering from breast cancer with a better opportunity for survival.

MATERIALS AND METHODS

Study design and setting: Prospective cross sectional study over a two and a half year period from 1st October 2003 to 31st March 2006 carried out at Kenyatta National Hospital (KNH) in the three surgical firms and the breast clinic. The KNH breast clinic was set up in the year 2000 as a specialist clinic for the purpose of managing all diseases of the breast. It is held once a week and run by consultant surgeons and surgical residents in training.

Study population: All patients seen at the KNH breast clinic or admitted to the three surgical wards with cytologically or histologically diagnosed advanced breast cancer were included in the study who consented to participate.

RESULTS

A total of 166 patients were recruited into the study. The mean age was 47 years with a range between 17 and 88 years. Females constituted 98.8%, had an average of 4.5 children per subject with a median of 4 and a range of 0-11. A lump as the first noticed symptom present in 87.3% and 52.1% were pre-menopausal. Only 11 (6.62%) patients presented within 30 days of discovering their breast symptom, 34 (20.4%) presented between thirty and ninety days and the remaining 115 (73.1%) presented three months after noticing their symptom. Three reasons accounted for 67.5% of the delay. Thirty three (19.9%) kept away fearing that they would be told they had cancer while 39 (23.5%) presented late because their breast symptom was painless. Another 40 (24.1%) said they had earlier visited medical personnel who had reassured them that their symptoms were benign.

Conclusion: Majority of patients treated for advanced breast disease presented to the healthcare providers at KNH more than three months after noticing their breast symptom and a sizeable number of patients were being reassured falsely that they have benign disease without the benefit of biopsy.
breast cancer (Manchester classification 1940-Stage III and IV) were included in this study. Patients who presented with previously treated or recurrent breast cancer were excluded from the study.

Data collection: All patients diagnosed with breast cancer who certified the inclusion criteria were interviewed by the researchers and socio-clinical and demographic data entered into a structured questionnaire after written consent was obtained from the patient or guardian.

Ethical issues: Written permission to do the study was granted by the Kenyatta National Hospital Research and Ethics Committee

RESULTS

A total of 166 patients were recruited into the study. The mean age was 47 years with a range between 17 and 88 years. Females constituted 98.8%. The study population had an average of four point five children per subject with a median of four and a range of 0-11. A lump as the first noticed symptom was seen in 87.3% and 52.1% were pre-menopausal. Table 1 summarizes the duration of symptoms in three groupings. Three reasons accounted for 67.5% of the delay. Thirty three (19.9%) kept away fearing that they would be told they had cancer while 39 (23.5%) presented late because their breast symptom was painless. Another 40 (24.1%) said they had earlier visited a medical personnel who had reassured them that their symptoms were benign. Table 2 gives more details of reasons given for the delay.

Table 1
Duration of symptoms

<table>
<thead>
<tr>
<th>Duration of symptoms</th>
<th>Number (n=166)</th>
<th>(%)</th>
<th>Cumulative percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 30 days</td>
<td>11</td>
<td>6.62</td>
<td>6.62</td>
</tr>
<tr>
<td>31- 90 days</td>
<td>34</td>
<td>20.40</td>
<td>27.02</td>
</tr>
<tr>
<td>&gt; 90 days</td>
<td>115</td>
<td>73.08</td>
<td>100.00</td>
</tr>
</tbody>
</table>

Table 2
Reasons for delayed presentation of patients with stage III and IV disease

<table>
<thead>
<tr>
<th>Reason for delay</th>
<th>Number (n=166)</th>
<th>(%)</th>
<th>Cumulative percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reassured that their condition was benign by the first medical personnel they visited</td>
<td>40</td>
<td>24.1</td>
<td>24.1</td>
</tr>
<tr>
<td>Painless symptomatology</td>
<td>39</td>
<td>23.5</td>
<td>47.6</td>
</tr>
<tr>
<td>Worried they would be diagnosed with cancer</td>
<td>33</td>
<td>19.9</td>
<td>67.5</td>
</tr>
<tr>
<td>Attending to traditional healers and taking herbal preparations</td>
<td>16</td>
<td>9.6</td>
<td>77.1</td>
</tr>
<tr>
<td>Not aware of the disease</td>
<td>13</td>
<td>7.8</td>
<td>84.9</td>
</tr>
<tr>
<td>others</td>
<td>25</td>
<td>15.1</td>
<td>100</td>
</tr>
</tbody>
</table>

DISCUSSION

For purposes of management, breast cancer is clinically divided into early and late disease. The former constitutes patients presenting with stage I and II, while the latter consists of stage III and IV according to Manchester classification 1940. Our present day knowledge of breast cancer is such that there is no effective primary prevention, making it imperative to detect the disease early in order to increase the likelihood of cure (8). There is indeed increasing evidence that patient delay at presentation adversely affects survival (6, 7). Richards et al. (9) found that a delay of 12 weeks or more resulted in significantly higher levels of recurrence and worse survival rates. In the West only one third (30%) of women presenting with symptomatic breast cancer have a patient delay of three or more months (10,11). Even then, presentation of breast cancer with advanced disease is rare in the developed world owing to awareness campaigns, limited practice of breast self examination (BSE) and widespread use of mammography screening (11). On the contrary, in developing countries and especially in Africa, presentation of breast cancer with stage III and stage IV is very common (1-5). In Nigeria over the last 40 years there has been progressive improvement in the stage at presentation of this disease. In the 1960’s Pearson found a late stage disease prevalence of 95%. This dropped to 84% in the 1970’s, 77% in the late 1980’s and 57% in the 1990’s (5). Comparatively at Muhimbili Medical Centre in Tanzania, Hiza and Aziz (3) found that up to 85% of patients with breast cancer presented with late stage disease in a study done between 1978 to 1982. In the same institution,
Despite high level of awareness this relatively cheap but effective tool is not being practised as often as it should as the level of skill and motivation required for effective BSE is high. Philip et al. (17) reported a prospective study of 304 patients with newly diagnosed breast cancer and established a BSE compliance rate of 54%. The compliant group was noted to present with clinically early tumours. A general survey in 63 hospitals in Italy found that BSE was practiced by 34% (n=1110) and that only 9% of these, did it regularly on a monthly basis (18). In this study any type of BSE (regular or irregular) resulted in smaller primaries at presentation. However, only in the regular group was there limited benefit in terms of nodal involvement and pathologic staging. It was also noted that the benefit that may accrue from timely presentation following BSE may be cancelled by delays inherent in out healthcare systems (18,19).

Indeed, one of the most talked about causes of delay at diagnosis continues to be physician reassurance to the patient that a breast lump is benign without the benefit of biopsy. This factor was quite prominent in this study where up to 24.1% gave this as the sole reason why they had presented with advanced breast disease. This emphasizes the importance that physicians must place on biopsy as a gold standard for the diagnosis of any lesion in the breast no matter how benign it may appear. Age and level of education are also independent factors likely to predict late stage disease at presentation. Ikpat et al (20) in Nigeria noted that 19.4% of patients aged 40 years and below presented with late stage disease compared to 73.3% of patients aged over 40 years. Personal, economic, physical and socio-cultural factors have also been documented to be causes of delay at presentation (21).

Breast size and presentation of breast disease initially without a lump have been known to cause delay (6,21). In Australia it was established that whether breast size was assessed in terms of weight or thickness (mastectomy specimen), large breasts presented consistently with larger tumours and more involvement of regional lymph nodes (21). Fear of mastectomy and its associated stigma led to late presentation in 2154 (44.7%) of all patients with breast cancer in Nigeria (22).

Preference from the onset for spiritual healing and traditional doctors accounted respectively for 13.5% and 23.1% of patient delay that resulted in presentation with advanced breast disease (19, 22-24).

ACKNOWLEDGEMENTS

To the Director, Kenyatta National Hospital for allowing us to access the hospital records and granting permission to publish this paper. I would also like to acknowledge the hard work done by H. Cherono and P. Oyiro who were medical students at the time.
REFERENCES


